Study of YOLT-202 in the Treatment of Alpha-1 Antitrypsin Deficiency (AATD)
Status:
ACTIVE_NOT_RECRUITING
Trial end date:
2027-03-01
Target enrollment:
Participant gender:
Summary
This is a single-arm, open-label, single-dose, dose-escalation exploratory study to evaluate the safety and tolerability of a single dose of YOLT-202 in patients with AATD and determine the optimal biologically active dose (OBD) of YOLT-202.